Article -> Article Details

Market Insights:

According to a report published by the Centers for Disease Control and Prevention (CDC) in 2014, over 14.1 million new cases of cancer were diagnosed all across the world. Other factors responsible for the expansion of the revenue generated from the market include increasing demand for DNA or gene chips, developments in the healthcare sector, increased investments, amplified research development activities, etc.

The implantable biological computers can be used in a wide range of applications where intercellular evaluation and treatment are required. The embracement of the technology is accelerating as it exhibits potential for fighting life-threatening diseases efficaciously. Market Research Future (MRFR) has recently published a report on the global biological computers market where it has unfolded that the market will grow at a robust pace of 7% CAGR during the forecast period 2017 to 2023.

The biological computers market, also known as DNA computers, is a new one with immense potential for growth. The DNA computers can analyze cellular activities for detecting mutated genes and all other activities of the genes found in cells. Biological computers enable the researchers to create biosensors system for identifying cancer cells. The increasing count of cancer patients is one of the key drivers of the market growth.

Market Segmentation:

By component, global biological computers market is segmented into hardware, software, input, and output.

By application, the global market for biological computers has been segmented into oncology, molecular genetics, Nano biotechnology, and others.

By end user, the biological computers market is segmented into pharmaceutical biotechnology companies, research centers, healthcare it companies, hospital clinics, and others.

Regional Analysis:

By region, the global biological computers market has been segmented into America, Europe, Asia Pacific, and, Middle East Africa. The America market will exhibit growth in demand owing to the rising burden of cancer in the region. It is estimated that 1,735,350 new cases of cancer will be registered in the U.S. in 2018. The fast-paced adoption of technology in the region will fuel demand for biological computers across the projection period.  Europe market is expected to thrive moderately from 2017 to 2023 due to increasing demand for healthcare IT solutions, clinical researches undertaken by associations, etc.

Asia Pacific is one of the fastest growing markets globally owing to increased investments in the healthcare sector backed by the governments. The region focuses on the evolution of the healthcare sector to boost medical tourism which is expected to accelerate the adoption of DNA computers over the assessment period. The increasing geriatric population is also favoring the growth of the market and will continue to show a similar trend throughout the forecast period. The primary contributors in the region will be India, China, and, Japan.

Middle East region will dominate the Middle East Africa market, which will exhibit a sluggish rate of market expansion owing to least technological penetration, lack of awareness about the benefits of biological computers, the poor economy of Africa, etc.

Competitive Dashboard:

Some of the key players profiled by MRFR in its report for gaining a deeper insight into the market include Microsoft (U.S.), IBM (U.S.), Illumina, Inc. (U.S.), IndieBio (U.S.), Sequenom Inc.(U.S.), Merck KGaA (U.S.), Bioneer Corporation (Republic of Korea), Wafergen Biosystems Inc. (U.S.), Thermofisher Scientific (U.S.), Emulate Inc. (U.S.), Macrogen Corp (Republic of Korea), Biometrix Technology Inc (U.S.), and Eurofins Genomics India Pvt Ltd. (India). The strategies developed and implemented by the market players leading to the growth and expansion of the market include research development, technological advancements, product developments, investments, etc.

Industry Developments:

Scientists at ETH Zurich in Switzerland have developed the world’s most complex biological computer, which is a group of engineered cells. It could be implanted into the body for detecting diseases and delivering treatments and is made up of nine cells.